EUVIMEDEUVIMED entdecken
Crossref

Interleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice

Yanyan Li, Yuqin Liao, Yiqi Miao, Changxiao Yu, Jinrong Long, Jiayu Wu, Jun Zuo, Zhen Zhang, Wei Dou, Xin Wang, Bo Zhang, Cuiyun Yu und 2 weitere

European Journal of Pharmacology · 2025-04 · 993 · 177366

DOI: 10.1016/j.ejphar.2025.177366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025-04. Verfasst von Yanyan Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, Universi…. Hauptthemen laut MEDLINE: Interleukins, RNA, Messenger, Orthomyxoviridae Infections, Pneumonia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza virus-induced pneumonia is a common complication caused by influenza A virus infection and causes severe lung inflammation. After infection, the body induces an active immune response that can produce cytokine storm, leading to increased expression of pro-inflammatory factors and tissue damage. Interleukin-35 (IL-35) is a recently identified cytokine associated with viral infection. IL-35 may inhibit the inflammation caused by viral infection and therefore may be developed into an antiviral treatment. Compared with traditional drugs, mRNA drugs have the advantages of simple production process, short development cycle, strong target specificity, high safety, and long-lasting action. In this study,we prepared IL-35 mRNA and IL-35 mRNA/Lipid Nanoparticle (IL-35 mRNA/LNP). To investigate the role of IL-35 mRNA in the host defense against post-influenza pneumonia, a mouse model of pneumonia caused by influenza infection was established. After influenza infection, the mice produced a large number of inflammatory factors that caused lung tissue damage, while administration of IL-35 mRNA/LNP effectively reduced the inflammatory response and improved the survival rate of mice. In addition, mice injected with IL-35 mRNA/LNP (125 μg/kg) directly via tail vein did not show significant inflammatory responses or tissue damage. These data suggest that IL-35 mRNA attenuates the inflammatory response caused by influenza virus infection and shows potential for development as a new drug for the treatment of influenza virus-induced pneumonia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsRNA, MessengerOrthomyxoviridae InfectionsPneumoniaAnimalsMiceNanoparticlesLungMice, Inbred BALB CDisease Models, AnimalFemaleMale

Stichwörter der Autor:innen

IL-35 mRNA/LNPInfluenza virus(H1N1)-Induced pneumoniaInterleukin-35SafetymRNA based therapy

Substanzen

InterleukinsRNA, Messengerinterleukin-35, mouse

Autor:innen und Institutionen

  • Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, PR China; Bioinformatics Center o…
  • Bioinformatics Center of AMMS, Beijing, 100850, PR China.
  • Bioinformatics Center of AMMS, Beijing, 100850, PR China; Department of Pharmacy, Peking Union Medical College Hospital (Dongdan Campus), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 10…
  • Department of Pharmacy, Peking Union Medical College Hospital (Dongdan Campus), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, PR China.
  • Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, PR China. Electronic address: 200…
  • Bioinformatics Center of AMMS, Beijing, 100850, PR China. Electronic address: yangjing@bmi.ac.cn.

Förderung

  • National Key Research and Development Program of China
  • Key Technologies Research and Development Program

Zitieren

APA

Li, Y., Liao, Y., Miao, Y., Yu, C., Long, J., Wu, J., Zuo, J., Zhang, Z., Dou, W., Wang, X., Zhang, B., Yu, C., Yang, J., & Wang, S. (2025). Interleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice. European Journal of Pharmacology, 993, 177366. https://doi.org/10.1016/j.ejphar.2025.177366

Vancouver

Li Y, Liao Y, Miao Y, Yu C, Long J, Wu J, et al. Interleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice. European Journal of Pharmacology. 2025;993:177366. doi:10.1016/j.ejphar.2025.177366

BibTeX
@article{Li2025,
  author = {Li, Yanyan and Liao, Yuqin and Miao, Yiqi and Yu, Changxiao and Long, Jinrong and Wu, Jiayu and Zuo, Jun and Zhang, Zhen and Dou, Wei and Wang, Xin and Zhang, Bo and Yu, Cuiyun and Yang, Jing and Wang, Shengqi},
  title = {Interleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice},
  journal = {European Journal of Pharmacology},
  year = {2025},
  volume = {993},
  pages = {177366},
  doi = {10.1016/j.ejphar.2025.177366}
}
Kostenlos starten →